Concepedia

Joseph E. Burgents

JE

29

Publications

5.1K

Citations

24

H-Index

2003

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Centre Hospitalier de l’Université de Montréal

AstraZeneca (United Kingdom)

Carolina Urologic Research Center

AstraZeneca (United States)

Joseph E. Burgents is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and urology.

Top concepts

Publications per year

2003–2025

29

Publications

29

Olaparib for Metastatic Castration-Resistant Prostate Cancer

Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 2.1K citations · Full text

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

Maha Hussain, Joaquı́n Mateo, Karim Fizazi et al. · New England Journal of Medicine · 2020 · 734 citations · Full text

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

Noel W. Clarke, Paweł Wiechno, B. Yа. Alekseev et al. · The Lancet Oncology · 2018 · 405 citations · Full text

, , +5

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · New England Journal of Medicine · 2024 · 240 citations · Full text

Rows per page

1–5 of 29